Retrograde aortic access during ventricular tachycardia ablation: Indications,techniques, and challenges

The retrograde aortic (RA) route is a widely used access route for mapping and ablation of ventricular tachycardias (VT) arising from the left ventricular endocardium. With the expanding role of VT ablation in patients with significant comorbidity, the choice between the RA and transseptal access routes is an increasingly important consideration. An individualized decision based on the location of the arrhythmogenic substrate, vascular anatomy, aortic valve morphology, and operator experience is necessary when deciding on the optimal access route. Among patients with challenging vascular anatomy, growing experience from structural interventions such as transcatheter aortic valve replacements and peripheral vascular interventions has provided valuable insights into techniques for safe retrograde access. The present review focuses on patient selection for RA access, potential complications associated with the technique, and optimal approaches for access in patients with challenging vascular or aortic valve anatomy.     

Incidence of nonsustained and sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator

INTRODUCTION: Nonsustained ventricular tachycardia (NSVT) is a frequent phenomenon in some patients with heart disease, but its association with sustained ventricular tachycardias (ventricular tachycardia [VT]/ventricular fibrillation [VF]) is still not clear. The aim of this study was to determine whether NSVT incidence was associated with sustained VT/VF in patients with an implantable cardioverter defibrillator (ICD). METHODS AND RESULTS: Retrospective data analysis was conducted in 923 ICD patients with a mean follow-up of 4 months. NSVT and sustained VT/VF were defined as device-detected tachycardias. The incidence rates of NSVT and sustained VT/VF as well as ICD therapies were determined as episodes per patient. The NSVT index was defined as the product of NSVT episodes/day times the mean number of beats per episode, i.e., total beats/day. The NSVT index peak was defined as the highest value on or prior to the day with sustained VT/VF episodes. Patients (n = 393) with NSVT experienced a higher incidence of sustained VT/VF (17.2 +/- 63.0 episodes/patient) and ICD therapies (15.2 +/- 61.4 episodes/patient) than patients (n = 530) without NSVT (sustained VT/VF: 0.5 +/- 6.6 and therapies: 0.5 +/- 5.6; P < 0.0001). Approximately 74% of NSVT index peaks occurred on the same day or <3 days prior to sustained VT/VF episodes. The index was higher for peaks < or =3 days prior to the day with sustained VT/VF (94.3 +/- 140.1 total beats/day) than for peaks >3 days prior to the day with sustained VT/VF (32.7 +/- 55.9 total beats/day; P < 0.0001). CONCLUSION: ICD patients with NSVT represent a population more likely to experience sustained VT/VF episodes with a temporal association between an NSVT surge and sustained VT/VF occurrence.     

Clinical significance and characteristics of exercise-induced ventricular tachycardia

Forty-seven patients (0.08%) from a total of 5,730 consecutive patients undergoing treadmill stress tests developed one or more episodes of ventricular tachycardia. Forty patients had heart disease, coronary artery disease being the leading cause. Rest ECG was normal in 12 patients and showed long QT (>440 msec) in 16 patients. Ventricular tachycardia was brief and self-terminating, requiring D/C cardloverston In only one patient. “Exertional hypotension” preceded ventricular tachycardia In 16 of 34 patients. There was poor correlation (r=0.16) between the rate of ventricular tachycardia (VT) and the underlying heart rate. Only four episodes of VT were Initiated by R on T premature ventricular beats. In summary, exercise-Induced ventricular tachycardia 1) Is a rare complication of treadmill stress test and occurs In patients with heart disease; 2) is frequently preceded by “exertional hypotension;” and 3) Is not related to the R on T phenomenon. The high incidence of prolonged QT may indicate a role for the autonomic nervous system in its pathogenesis.     

第四代埋藏式自动复律除颤器的临床应用

2例冠心病,陈旧心肌梗塞并持续室性心动过速的病人,服用2～3种抗心律失常药无效而考虑埋藏式自动复律除颤器(ICD)治疗.术前电生理检查均诱发了持续室速,并了解了诱发和终止条件.经锁骨下静脉穿刺安装了第四代ICD.术后随访7～12个月中,2例均有室速发作而正确放电,但1例有窦性心动过速被误感知现象,经程序调整而消失.本文强调了适应症选择,术前电生理检查和术后随访的重要性.     

Amiodarone in Pediatric Patients

The reported world clinical experience of amiodarone in children is revieived; the known age-dependent electro physiological and pharmacokinetic characteristics of amiodarone are examined; and guidelines for the use of amiodarone in children are suggested.     

急性心肌梗死非持续和持续室性心动过速的Q—T离散度

为研究急眭心肌梗死伴持续和非持续室性心动过速患者间Q-T离散度和其它心电图参数之间的关系。比较14例急性心肌梗死伴持续室性心动过速和26例伴非持续室性心动过速患者的心室Q-T离散度、Q-T和Q-T_c间期。结果显示持续和非持续室性心动过速患者之间的Q-T离散度以及相邻胸导联Q-T离散度差异有显著意义(110.1±7.80对80.8±4.4,105.9±6.9对67.6±4.0,P<0.01)。我们认为相邻导联Q-T离散度增大极易出现室性心动过速,Q-T离散度大于110ms有发生持续室性心动过速的危险。而Q-T离散度在80—110ms之间有非持续室性心动过速的可能性。     

Effect of Basic Drive Train Cycle Length on Induction of Ventricular Tachycardia by a Single Extrastimulus

This study determined the effects of a wide range of basic drive cycle lengths on the induction of ventricular tachycardia (VT) by a single extrastimulus (S₂). Seventy-one patients with coronary artery disease and inducible sustained monomorphic VT underwent 121 electrophysiology tests either in the control state or during treatment with an antiarrhythmic drug. Ventricular basic drive trains were eight beats in duration and the intertrain interval was three seconds. Programmed ventricular stimulation was performed with S₂ using the longest possible basic drive cycle length rounded off to the nearest multiple of 100 msec, then using basic drive train cycle lengths that decreased in 100 msec steps to 400 msec, and finally using a basic drive cycle length of 350 msec. At each drive cycle length, an interval of > 50 msec beyond the effective refractory period (ERP) was scanned with S₂. Monomorphic VT was induced by S₂ in 52/121 studies (43%). The drive cycle length had a significant linear effect on the log odds of inducing VT (P < 0.0001). The highest yield of VT occurred with a drive cycle length of 350 msec (42/121, 34%), and with each increment in drive cycle length, the expected odds of inducing VT decreased by a factor of 1.7. In 88% of cases in which VT was induced at a particular drive cycle length but not at longer drive cycle lengths, the coupling intervals that induced VT exceeded the ERP measured at one or more of the longer basic drive cycle lengths. In conclusion, there is an inverse relationship between the basic drive cycle length and the yield of monomorphic VT induced by S₂. The use of shorter basic drive cycle lengths often facilitates the induction of VT by some effect other than critical shortening of the S₂ coupling interval.     

Long‐Term Outcome After Catheter Ablation for Left Posterior Fascicular Ventricular Tachycardia Without Development of Left Posterior Fascicular Block

Long‐Term Outcome After Substrate‐Based Ablation of LPF VT During SR . Background: Catheter ablation of left posterior fascicular (LPF) ventricular tachycardia (VT) is commonly performed during tachycardia. This study reports on the long‐term outcome of patients undergoing ablation of LPF VT targeting the earliest retrograde activation within the posterior Purkinje fiber network during sinus rhythm (SR). Methods: This study retrospectively analyzed 24 consecutive patients (8 female; mean age 26 ± 11 years) referred for catheter ablation of electrocardiographically documented LPF VT. Programmed stimulation was performed to induce tachycardia, while mapping and ablation was aided by use of a 3D electroanatomical mapping system. Catheter ablation targeted the earliest potential suggestive of retrograde activation within the posterior Purkinje fiber network (retro‐PP) recorded along the posterior mid‐septal left ventricle during SR if LPF VT was noninducible. Results: Overall, 21/24 (87.5%) patients underwent successful catheter ablation in SR targeting the earliest retro‐PP, while 3/24 (12.5%) patients were successfully ablated during tachycardia. In none of the patients, ablation resulted in LPF block. No procedure‐related complications occurred. After a median follow‐up period of 8.9 (4.8–10.9) years, 22/24 (92%) patients were free from recurrent VT. Conclusion: In patients presenting with LPF VT, ablation of the earliest retro‐PP along the posterior mid‐septal LV during SR results in excellent long‐term outcome during a median follow‐up period of almost 9 years. (J Cardiovasc Electrophysiol, Vol. 23, pp. 1179–1184, November 2012)     

Proarrhythmic and antiarrhythmic effects of intravenous prostacyclin in man

Prostacyclin (PGI2) has been shown to reduce the occurrenceof experimental ventricular arrhythmias. To assess potentialbeneficial effects in man, the electrophysiological action ofPG12 was studied in 16 non medicated patients. The protocolused in incremental pacing and programmed stimulation in theright atrium and ventricle. This protocol and measurement ofeffective refractory periods (ERP) were performed before andduring the injection of 2.5, 5 and 10 ng kg^–1 min^–1of PGI2. The atrial functional refractory period decreased significantly(P<0.05); PGI2 had no influence on the occurrence of induciblenon-sustained (NS) atrial tachycardias and was responsible forthe occurrence of 2 non-sustained atrial tachycardias in 8 patientswith inducible atrial echo beats under basal conditions. Thirteenpatients did not have inducible ventricular tachycardia ( VT)under basal conditions. Non-sustained VT was induced after PGI2in 4 of them but in only 1 of them after the administrationof propranolol. Three patients had inducible VT under basalconditions (1 non-sustained, 2 sustained VT). PG12 did not preventthe occurrence of VT (1 non-sustained, 1 sustained VT), exceptin 1 patient with ischaemic-related VT, who had non-sustainedVT after PGI2. In conclusion, PGI2 does not seem to have a cardiacantiarrhythmic effect and may increase the atrial and ventricularrepetitive response. This effect could be related to an increaseof adrenergic tone.     

A Case with Occurrence of Antidromic Tachycardia After Ablation of Idiopathic Left Fascicular Tachycardia: Mechanism of Left Upper Septal Ventricular Tachycardia

A 36‐year‐old male presented with verapamil‐sensitive narrow QRS tachycardia. The patient underwent the catheter ablation of common idiopathic left fascicular ventricular tachycardia (ILVT) 2 years ago. During narrow QRS tachycardia, the diastolic and presystolic potentials (P1 and P2) were recorded at the left septum. Activation sequences of P1 and P2 were opposite from those in common ILVT. Entrainment of P1 at the upper septum exhibited concealed fusion and S‐QRS equal to P1‐QRS. Radiofrequency current to P1 suppressed VT. Idiopathic left upper septal VT might be the antidromic macroreentry of the common form of ILVT.     

Catheter‐Based Cryoablation of Postinfarction and Idiopathic Ventricular Tachycardia: Initial Experience in a Selected Population

Cryoablation of Ventricular Tachycardia. Introduction: Transvenous cryoablation has proven to be safe and effective for the treatment of supraventricular arrhythmias. The aim of this prospective study was to report the feasibility and safety of catheter‐based cryoablation for the treatment of postinfarction and idiopathic ventricular tachycardia (VT). Methods and Results: Catheter‐based cryoablation was performed in 17 patients (15 men, 58 ± 18 years). VT occurred after a prior myocardial infarction in 10 and was idiopathic in 7 patients. Cryoablation was performed with a 10‐F, 6.5‐mm tipped catheter. The ablation site was selected using entrainment mapping techniques for postinfarction VT. The site of the earliest activation time with optimal pace mapping was used for ablation of idiopathic VT. All targeted VTs (12 postinfarction and 7 idiopathic) were acute successfully ablated after a median number of 2 applications of 5 minutes with an average temperature of –82 ± 4°C. Mean procedure and fluoroscopy times were 204 ± 52 and 52 ± 20 minutes for postinfarction VT and 203 ± 24 and 38 ± 15 minutes for idiopathic VT. No cryocatheter or cryoenergy complications were observed. After a follow‐up of 6 months, 4 of the 10 patients with postinfarction VT had a recurrence. In 1 of the 7 patients with idiopathic VT the index arrhythmia recurred. Conclusion: In this small patient population, catheter‐based cryoablation of VT was safe and effective. Future studies are needed to evaluate the effect of cryothermy in a larger group of patients, especially those with postinfarction VT. (J Cardiovasc Electrophysiol, Vol. 21, pp. 255–261, March 2010)     

Idiopathic verapamil-sensitive sustained left ventricular tachycardia

Idiopathic verapamil-sensitive left ventricular tachycardia (VT) has characteristic QRS configurations during VT: right bundle-branch block with either left axis or right axis (less common) deviation. QRS duration is relatively narrow (0.13-0.16s) and frequently endocardial activation prior to QRS is recorded during VT, which is the basis of its being called fascicular tachycardia. The mechanism is probably reentry, but the nature of the slow conduction necessary for the occurrence of reentry is quite different from that of other sustained monomorphic VT associated with structural heart disease. Chronic oral verapamil therapy is the drug of choice for alleviation of symptoms. Long-term prognosis is good.     

Diagnosis and Ablation of Multiform Fascicular Tachycardia

Ablation Multiform Fascicular Tachycardia . Introduction: Fascicular tachycardia (FT) is an uncommon cause of monomorphic sustained ventricular tachycardia (VT). We describe 6 cases of FT with multiform QRS morphologies. Methods and Results : Six of 823 consecutive VT cases were retrospectively analyzed and found attributable to FT with multiform QRS patterns, with 3 cases exhibiting narrow QRS VT as well. All underwent electrophysiology study including fascicular potential mapping, entrainment pacing, and electroanatomic mapping. The first 3 cases describe similar multiform VT patterns with successful ablation in the upper mid septum. Initially, a right bundle branch block (RBBB) VT with superior axis was induced. Radiofrequency catheter ablation (RFCA) targeting the left posterior fascicle (LPF) resulted in a second VT with RBBB inferior axis. RFCA in the upper septum just apical to the LBB potential abolished VT in all cases. Cases 4 and 5 showed RBBB VT with alternating fascicular block compatible with upper septal dependent VT, resulting in bundle branch reentrant VT (BBRT) after ablation of LPF and left anterior fascicle (LAF). Finally, Cases 5 and 6 demonstrated spontaneous shift in QRS morphology during VT, implicating participation of a third fascicle. In Case 6, successful ablation was achieved over the proximal LAF, likely representing insertion of the auxiliary fascicle near the proximal LAF. Conclusions : Multiform FTs show a reentrant mechanism using multiple fascicular branches. We hypothesize that retrograde conduction over the septal fascicle produces alternate fascicular patterns as well as narrow VT forms. Ablation of the respective fascicle was successful in abolishing FT but does not preclude development of BBRT unless septal fascicle is targeted and ablated. (J Cardiovasc Electrophysiol, Vol. 24, pp. 297‐304, March 2013)     

Efficacy of flecainide in pacing-induced sustained ventricular tachyarrhythmias: correlation to clinical parameters and tachycardia-characteristics

Seventy-two patients with sustained ventricular tachycardiaor syncope of unknown origin underwent electrophysiologic evaluationbefore and after therapy with flecainide (200–300 mg day^–1).In all patients, sustained ventricular tachycardia or ventricularfibrillation was inducible during control electrophysiologicstudy. During flecainide therapy, sustained ventricular tachycardia(VT) was no longer inducible in 18 patients (25%) whereas in54 patients, VT was still inducible. In five of the latter patients,VT became more difficult to induce (overall efficacy 32%). Therate of VT decreased from 214±49 beats min^–1 duringthe control electrophysiologic study to 178±48 beatsmin^–1 during flecainide (P<0.01). The ERP of the rightventricle increased from 251±27 ms during the controlstudy to 267±34 ms on flecainide (P<0.01). Mean ejectionfraction and mean LVEDP did not differ between responders andnon-responders, yet the presence of a left ventricular aneurysmcorrelated with a lack of antiarrhythmic response to flecainide.VT rate as well as VT morphology during the control study discriminatedbetween responders and non-responders; 11% of patients withVT-rate 230 beats min^–1 responded to oral flecainidecompared with 31% with a VT rate > 230 beats min^–1at control. 26% with induced monomorphic VT responded, comparedwith 100% with induced VF during the control study. 18 of 23responders were discharged on flecainide. During a mean follow-upof 26±18 months, two patients experienced a recurrenceof VT and in one patient, flecainide had to be discontinueddue to side-effects. Thus, the acute efficacy of flecainide, evaluated by serialdrug testing, correlates with haemodynamic parameters and thecharacteristics of tachycardia.     

Tachycardia induced tachycardia: case report of right ventricular outflow tract tachycardia and AV nodal reentrant tachycardia

Tachycardia induced tachycardia, or so called double tachycardia, is rare. A 34 year old woman is described who had a history of syncope, frequent extrasystoles, and episodes of non-sustained ventricular tachycardia, perceived as palpitation, without syncope. At electrophysiological study, during infusion of isoprenaline, an episode of non-sustained ventricular tachycardia arising from the right ventricular outflow tract initiated sustained atrioventricular nodal reentrant tachycardia, thought to be the cause of the patient's syncope. Ablation of the right ventricular outflow tract focus abolished the ventricular ectopy; the slow AV nodal pathway was also ablated. The patient no longer has either syncope or palpitation.     

Clinical Experience with Orthocor II Antitachycardia Pacing System for Recurrent Tachyarrhythmia Termination

Between June 1986 and December 1988, eight patients were treated with an Orthocor II 284 A antitachycardia pacemaker (Cordis Corp., Miami, FL, USA) forsupraventricular tachycardia (SVT) and ventricular tachycardia (VT) termination. Four patients had intra-AV nodal reentrant tachycardias; 1 patient had AV reentrant tachycardia with an atrio-nodal accessory bypass tract; 2 patients had AV reentrant tachycardias with concealed Kent bundle, and 1 patient had ventricular tachycardia. All patients had been treated with three or more drugs and were considered to be drug refractory. The programmed antitachycardia mechanism used for patients with SVT were: automatic overdrive in five patients and burst scanning in two patients. In the patient with VT, a critically timed double extrastimulus with fixed coupling interval was programmed. Follow-up ranged from 2 to 30 months. The pacemaker proved to be effective in terminating tachycardias in all cases with SVT; in the patient with VT, the programmed antitachycardia mechanism was effective for a long time, but after an episode of sustained VT not interrupted by the pacemaker, the patient underwent automatic cardioverter/defibrillator (AICD) implantation. Additional antiarrhythmic therapy was required in 3 patients to control their maximum sinus rate, in 1 patient to reduce tachycardia episodes and to enable termination, and in 2 patients to prevent spontaneous atrial fibrillation. It is concluded that Orthocor II is a flexible and versatile antitachycardia pacemaker providing a safe and effective control of recurrent tachycardia in selected patients.